Clinical Study
Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma
Table 3
The serum SALL4 levels in HCC and controls (pg/mL).
| ||||||||||||||||||||||||||||||||
HCC: hepatocellular carcinoma. |
| ||||||||||||||||||||||||||||||||
HCC: hepatocellular carcinoma. |